Skip to main content
Tuoxin Pharmaceutical Group Co.,Ltd. logo

Tuoxin Pharmaceutical Group Co.,Ltd. — Investor Relations & Filings

Ticker · 301089 ISIN · CNE100004YC3 Shenzhen Stock Exchange Manufacturing
Open in API
Filings indexed 734 across all filing types
Latest filing 2023-01-17 Board/Management Inform…
Country CN China
Listing Shenzhen Stock Exchange 301089

About Tuoxin Pharmaceutical Group Co.,Ltd.

https://www.tuoxinpharm.com

Tuoxin Pharmaceutical Group Co., Ltd. specializes in the research, development, production, and distribution of nucleosides and nucleotides. The company serves as a major global supplier of active pharmaceutical ingredients (APIs) and chemical intermediates. Its core product portfolio includes cytidine, inosine, guanosine, adenosine, and their various derivatives, which are essential components in the synthesis of antiviral, anti-tumor, and cardiovascular medications. Notably, the group provides key intermediates for drugs such as Ribavirin and Azvudine. Tuoxin Pharmaceutical leverages advanced synthetic biotechnology and large-scale manufacturing capabilities to support the global pharmaceutical industry. The company maintains a focus on technological innovation and quality control to ensure the stability and purity of its chemical products for diverse therapeutic applications.

Recent filings

Filing Released Lang Actions
独立董事关于第四届董事会第二十次会议相关事项的独立意见
Board/Management Information Classification · 95% confidence The document is an independent opinion from the independent directors regarding matters discussed at the 20th meeting of the 4th board of directors. It includes their review and approval of proposals related to changes in the implementation of certain fundraising projects and expected related-party transactions for 2023. The document references compliance with stock exchange rules and company bylaws but does not contain financial statements or detailed financial data. It is a governance-related document expressing independent directors' opinions on board matters rather than a full management report or financial report. Therefore, it fits best under Board/Management Information (MANG), which covers announcements related to board activities and decisions.
2023-01-17 Chinese
第四届董事会第二十次会议决议公告
Board/Management Information Classification · 95% confidence The document is titled as a resolution announcement from the company's fourth board meeting, detailing decisions made by the board of directors. It includes meeting attendance, voting results, and approvals of various company matters such as changes in project implementation, related party transactions, credit applications, guarantees, and scheduling of a shareholders meeting. There is no financial data or report content, but rather a formal announcement of board meeting resolutions. This fits the category of Board/Management Information (MANG), which covers announcements of changes or decisions by the board of directors.
2023-01-17 Chinese
关于变更部分募投项目实施地点、实施方式、实施主体的公告
Capital/Financing Update Classification · 95% confidence The document is a formal announcement by Xinxiang Tuoxin Pharmaceutical Co., Ltd. regarding changes to the implementation location, method, and entity of certain projects funded by raised capital. It details the original fundraising, the use of funds, and the specific changes approved by the board and supervisory committee, including independent directors and the sponsor's opinions. The document references regulatory guidelines related to the management and use of raised funds and states that the changes will be submitted to the shareholders' meeting for approval. The content focuses on the management and use of capital raised from a public offering, specifically changes to the investment projects funded by that capital. It is not a full financial report, audit report, or earnings release, nor is it a call transcript or AGM materials. It is an update on capital/financing activities related to the use of raised funds and changes in project implementation. The document length is 4423 characters, which is substantive and contains detailed information about the capital use changes, not merely an announcement of a report. Therefore, the most appropriate classification is Capital/Financing Update (CAP).
2023-01-17 Chinese
关于召开2023年第一次临时股东大会的通知
Proxy Solicitation & Information Statement Classification · 95% confidence The document is a detailed notice about convening the 2023 first extraordinary general meeting (临时股东大会) of shareholders for a company, including information on meeting date, voting procedures (both onsite and online), registration details, agenda items, and proxy forms. It does not contain financial statements, audit results, or management discussion of financial performance. It is not a report of voting results but a notice to shareholders about the meeting and how to participate and vote. Therefore, it fits the category of a Proxy Solicitation & Information Statement (PSI), which includes materials sent to shareholders to provide information and request votes for meetings.
2023-01-17 Chinese
中天国富证券有限公司关于新乡拓新药业股份有限公司变更部分募集资金投资项目实施主体、实施地点、实施方式的核查意见
Capital/Financing Update Classification · 95% confidence The document is a detailed report from a sponsoring securities company regarding changes to the implementation subject, location, and method of investment of part of the funds raised by Xinxiang Tuoxin Pharmaceutical Co., Ltd. It references regulatory approvals, board and shareholder meetings, and compliance with Shenzhen Stock Exchange rules. The document includes specifics about the fundraising, investment projects, and changes approved by the board and shareholders. It is not a brief announcement but a substantive report on the use of raised funds and related changes, including audit and verification opinions. This fits the definition of a Capital/Financing Update (CAP), as it provides updates on the use and changes in the company's fundraising investment projects and capital deployment. The document length is under 5,000 characters but contains detailed substantive content, not merely an announcement or certification. Therefore, the best classification is CAP with high confidence.
2023-01-17 Chinese
关于预计2023年日常性关联交易的公告
Regulatory Filings Classification · 95% confidence The document is an announcement regarding the company's expected daily related party transactions for the year 2023. It includes details about the nature of the transactions, estimated amounts, related parties, and opinions from independent directors and the sponsoring institution. The document does not contain comprehensive financial statements or detailed financial performance data but focuses on disclosure of related party transactions and their compliance with regulations. It is not an annual report, interim report, earnings release, or any other financial report type. It is a regulatory announcement about related party transactions, which fits best under Regulatory Filings (RNS). The document length is 4565 characters, which is moderate, and the content is detailed but not a full financial report. Therefore, the classification is Regulatory Filings (RNS) with high confidence.
2023-01-17 Chinese

Browse filings by year

6 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.